Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting
- PMID: 11241503
- DOI: 10.1002/1097-0320(20010215)46:1<23::aid-cyto1033>3.0.co;2-z
Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting
Erratum in
- Cytometry 2001 Apr 15;46(2):119
Abstract
At the ISAC 2000 Congress, the Clinical Cytometry Society organized a meeting of international experts to reach consensus on the minimum number of antibodies required for a full evaluation of hematologic and lymphoid neoplasias. A questionnaire was distributed prior to the meeting to numerous experts from US and European institutions and 13 responses were received. At the meeting, 25 individuals, including most of those who returned responses, participated in the discussions and voted on the issues presented. In chronic lymphoproliferative disorders (CLD), 9 antibodies (anti-CD5, CD19, kappa, lambda, CD3, CD20, CD23, CD10, and CD45) were deemed essential for initial evaluation by 75% of the participants. There was near unanimity that additional markers (selected from CD22, FMC7, CD11c, CD103, CD38, CD25, CD79b and heavy chains for B-cell disorders, and CD4, CD7, CD8, CD2, CD56, CD16, TCRa/b, and TCRg/d for T-cell disorders) would be needed to fully characterize CLD, although not every marker would be useful in all cases. Tissue lymphomas were believed to be similar to CLD, needing a minimum of 12--16 markers. However, for some cases, CD30, bcl-2, TdT, CD71, CD1a, and CD34 were cited as useful by the participants. Markers mentioned for plasma cell disorders included kappa, lambda, CD38, CD45, CD56, CD19, CD20, CD138, and heavy chains. Of 17 voting participants, 16 agreed that between 5 to 8 markers would be essential reagents for plasma cell disorders. For acute leukemia (AL), 10 markers (CD10, CD19, CD13, CD33, CD34, CD45, CD7, CD14, CD3, and HLADR) were considered essential by 75% of participants for initial characterization of the leukemia lineage. Most (>75%) agreed that at least one more B (CD20, CD22, CD79a, IgM), T (CD1a, CD2, CD4, CD5, CD8), myeloid (CD11b, CD15, CD64, CD117, myeloperoxidase), erythroid (CD36, CD71, glycophorin A), and megakaryocytic (CD41, CD61) reagents should be included in the essential panel. However, there was no agreement as to which was optimal. Thus, approximately 13--15 of those reagents would be considered essential in all cases of AL, whereas others (CD16, CD56, CDw65, TdT, and cytoplasmic CD3) were mentioned as useful in some cases. Almost all voting participants believed that the appropriate number of markers for complete characterization of AL would average 20--24. The majority of the responders (11 of 13) indicated that fewer reagents could be used in monitoring or staging patients with previously characterized disease, but not all ventured a specific number of reagents. From the above results, we conclude that the phenotypic analysis of hematologic and lymphoid neoplasia requires a rather extensive panel of reagents. Supplementary reagents might even be necessary if they prove to become relevant for diagnostic purposes. Reducing the number of antibodies could significantly compromise the diagnostic accuracy, appropriate monitoring, or therapy of these disorders.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.Leukemia. 2002 Aug;16(8):1460-9. doi: 10.1038/sj.leu.2402584. Leukemia. 2002. PMID: 12145686
-
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].Ai Zheng. 2007 Apr;26(4):418-22. Ai Zheng. 2007. PMID: 17430665 Chinese.
-
[Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].Zhonghua Xue Ye Xue Za Zhi. 2007 Nov;28(11):731-6. Zhonghua Xue Ye Xue Za Zhi. 2007. PMID: 18457262 Chinese.
-
Lymphoblastic lymphoma.Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. doi: 10.1016/j.critrevonc.2010.12.003. Epub 2011 Jan 26. Crit Rev Oncol Hematol. 2011. PMID: 21273093 Review.
-
Immunophenotyping of selected hematologic disorders--focus on lymphoproliferative disorders with more than one malignant cell population.Int J Lab Hematol. 2013 Jun;35(3):275-82. doi: 10.1111/ijlh.12080. Int J Lab Hematol. 2013. PMID: 23590655 Review.
Cited by
-
Applied Protein and Molecular Techniques for Characterization of B Cell Neoplasms in Horses.Clin Vaccine Immunol. 2015 Nov;22(11):1133-45. doi: 10.1128/CVI.00374-15. Epub 2015 Aug 26. Clin Vaccine Immunol. 2015. PMID: 26311245 Free PMC article.
-
Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A.Hematol Rep. 2018 Dec 12;10(4):7823. doi: 10.4081/hr.2018.7823. eCollection 2018 Nov 6. Hematol Rep. 2018. PMID: 30631409 Free PMC article.
-
Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry.Diagn Pathol. 2008 Nov 6;3:43. doi: 10.1186/1746-1596-3-43. Diagn Pathol. 2008. PMID: 18986555 Free PMC article.
-
Flowcytometric comparative analysis in acute leukemias between Indian and proposed minimal screening panel.Med J Armed Forces India. 2016 Jul;72(3):220-30. doi: 10.1016/j.mjafi.2016.01.002. Epub 2016 Mar 29. Med J Armed Forces India. 2016. PMID: 27546960 Free PMC article.
-
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.Leukemia. 2012 Sep;26(9):1908-75. doi: 10.1038/leu.2012.120. Epub 2012 May 3. Leukemia. 2012. PMID: 22552007 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous